NICHOLASVILLE, Ky., Feb. 4, 2011 /PRNewswire/ -- MediVet-America, the leading developer of in-clinic stem cell regenerative therapy for animals suffering from osteoarthritis, hip dysplasia, ligament and cartilage injuries and similar ailments, ended its first year of business having achieved record advances in size and scope.
Using MediVet-America's new Adipose-Derived Stem Cell Procedure Kit and equipment, veterinary practitioners perform the drug-free procedure entirely in their own clinics, in one day, more quickly, effectively and economically than first-generation animal stem cell therapy.
This new treatment, previously only available in Australia and New Zealand, was launched in the United States, Canada, South America and Hong Kong in 2010.
Over the past year, MediVet-America has signed agreements with more than 100 leading veterinarians and clinics, 12 distributor territories in 20 states and four provinces in Canada, providing vets with the ability to perform in-house stem cell procedures that can lengthen and rejuvenate the quality of life for adult dogs, cats and horses experiencing lameness, pain, and a restricted range of motion. Before stem cell therapy, veterinarians were limited to prescribing anti-inflammatory medicine or performing expensive surgery.
In December, the company launched MediVet Lab Services in Lexington, KY, that provides technical support for in-clinic animal stem cell procedures, regional and national Adipose Stem Cell Processing, Cryogenic Banking Services, Autologous Conditional Serum Processing, and Cell Counting Services for stem cell treatments.
MediVet-America Managing Director Jeremy Delk envisions opening additional labs throughout the U.S. that will also provide an interactive web site with an online vet certification program and a quality assurance/control program encompassing cell counts and sterility.
"We experienced a tremendous year of growth in all areas of our busi
Copyright©2010 PR Newswire.
All rights reserved